Research by Dr. Turner and team highlights pitfall of psychiatric drug development

Physicians who prescribe antipsychotic medications may be basing their decisions on incomplete information, according to new research published by scientists at Oregon Health & Science University. The study is published in PLoS Medicine, a peer-reviewed open-access journal published by the Public Library of Science.

This latest research follows a highly publicized 2008 report in the New England Journal of Medicine demonstrating that antidepressant drug trials were selectively published, exaggerating their apparent effectiveness. This follow-up study suggests that similar concerns exist, though to a somewhat lesser extent, with antipsychotic drugs. 

The authors reached these conclusions by reviewing 24 FDA-registered premarketing trials for eight second-generation antipsychotics—aripiprazole (Abilify), iloperidone (Fanapt), olanzapine (Zyprexa), paliperidone (Invega), quetiapine (Seroquel), risperidone (Risperdal), risperidone long-acting injection (Consta), and ziprasidone (Geodon). They then compared the results in the FDA's review documents to the results presented to clinicians and researchers in medical journals.

Read more »